EligibleTrials

Clinical trials recruiting for Familial Adenomatous Polyposis

13
Recruiting trials
28
US states with sites
7
Countries
8%
Accept healthy volunteers

Phase breakdown

Phase 1 2Phase 2 1Phase 3 1Not applicable 10

Drugs and treatments being studied

InterventionTrials
Dordaviprone Hydrochloride1
R-1,3-Butanediol (10G-A)1
R-1,3-Butanediol (20G-A)1
R-1,3-Butanediol (30G-A)1
R-1,3-Butanediol (30G-B)1
REC-48811
celecoxib and metformin combination1
celecoxib monotherapy1

Where trials are recruiting (top US states)

StateRecruiting trials
Michigan3
Missouri3
Ohio3
Texas3
Florida2
Indiana2
Minnesota2
Pennsylvania2
Tennessee2
Arizona1
California1
Colorado1

Top cities

Houston, Texas 3Ann Arbor, Michigan 2Cleveland, Ohio 2Philadelphia, Pennsylvania 2St Louis, Missouri 2Aitkin, Minnesota 1Alliance, Ohio 1Aurora, Illinois 1Bozeman, Montana 1Brainerd, Minnesota 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Familial Adenomatous Polyposis often also study these conditions. Each links to its own recruiting-trial list.

Colorectal cancer 1359Pancreatic cancer 870Melanoma 487Lynch Syndrome 28FAP 5Breast cancer 2239Von Hippel-Lindau Disease 6Vaginal Cancer 7Urethral Cancer 4Ureter Cancer 3

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Familial Adenomatous Polyposis trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.